Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 67.44B 59B 54.41B 50.34B 95.54B 6,437B 97.14B 652B 255B 3,161B 253B 248B 10,950B P/E 2026 *
17.2x
P/E 2027 * 13.8x
Enterprise Value 59.61B 52.14B 48.09B 44.49B 84.45B 5,690B 85.86B 576B 226B 2,794B 224B 219B 9,678B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.24x
Free-Float
72.33%
Yield 2026 *
0.59%
Yield 2027 * 0.67%
1 day+0.43%
1 week+1.80%
Current month+6.81%
1 month+8.09%
3 months-13.26%
6 months-16.39%
Current year-13.71%
1 week 637.72
Extreme 637.715
677.92
1 month 594.9
Extreme 594.9
677.92
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 31/12/2000
Chief Executive Officer 73 07/01/1988
Director of Finance/CFO 55 04/02/2024
Director TitleAgeSince
Chairman 73 08/06/2023
Director/Board Member 85 31/05/1991
Director/Board Member 85 31/05/1991
Date Insider Type Main position Quantity % Market Cap.
07-01Sell

Director

-200 0.0002%
04-30Sell

Director

-100 0.0001%
03-31Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+1.80%+20.53%-5.31% 67.44B
+0.52%-5.52%+46.80%+218.71% 53.98B
-2.79%+32.50%+32.50%+32.50% 41.77B
+0.99%+6.05%-48.96%-52.97% 41.15B
-0.43%-7.62%+50.09%-29.10% 29.58B
+2.72%-4.91%+131.31%-38.38% 29.28B
+0.81%+1.14%+71.99%+90.97% 23.43B
+0.17%+8.48%+4.86%+185.45% 19.11B
+1.14%-0.17%+68.83%+134.48% 16.82B
+17.24%+18.93%+99.65%+428.80% 15.36B
Average +2.08%+1.68%+47.76%+96.52% 33.79B
Weighted average by Cap. +1.05%+1.23%+38.61%+68.55%

Financials

2026 *2027 *
Net sales 15.87B 13.89B 12.81B 11.85B 22.49B 1,515B 22.86B 153B 60.12B 744B 59.59B 58.3B 2,577B 17.55B 15.35B 14.16B 13.1B 24.86B 1,675B 25.28B 170B 66.46B 823B 65.88B 64.45B 2,849B
Net income 4.06B 3.55B 3.28B 3.03B 5.75B 388B 5.85B 39.24B 15.38B 190B 15.25B 14.92B 660B 5.11B 4.47B 4.12B 3.81B 7.23B 487B 7.35B 49.32B 19.33B 239B 19.17B 18.75B 829B
Net Debt -7.83B -6.85B -6.32B -5.85B -11.1B -748B -11.28B -75.68B -29.67B -367B -29.41B -28.77B -1,272B -10.5B -9.19B -8.47B -7.84B -14.88B -1,002B -15.13B -101B -39.77B -492B -39.42B -38.57B -1,705B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
09/07/26 US$666.03 +0.47% 291,767
08/07/26 US$662.88 -1.97% 746,834
07/07/26 US$676.23 +4.07% 918,937
06/07/26 US$649.81 -0.68% 714,338
02/07/26 US$654.27 +4.73% 1,071,604
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
662.88USD
Average target price
822.48USD
Spread / Average Target
+24.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock